Search research articles
Contact Us
Filters
Showing results (371-380 of 499) with videos related to
Page
of 50
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2021
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero, Axel Grothey, Eric Van Cutsem, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
March 13, 2021
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study
Wasat Mansoor, Hendrik-Tobias Arkenau, Maria Alsina, et al.
Future Oncology (London, England)
|
July 18, 2020
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements
Tanios S Bekaii-Saab, Juan W Valle, Eric Van Cutsem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2022
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Hedy L Kindler, Pascal Hammel, Michele Reni, et al.
The New England Journal of Medicine
|
June 4, 2019
Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer
Talia Golan, Pascal Hammel, Michele Reni, et al.
The Oncologist
|
March 31, 2010
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery
Sabine Tejpar, Monica Bertagnolli, Fred Bosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
90Y-edotreotide for metastatic carcinoid refractory to octreotide
David L Bushnell, Thomas M O'Dorisio, M Sue O'Dorisio, et al.
Annals of Surgery
|
February 9, 2012
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)
Halfdan Sorbye, Murielle Mauer, Thomas Gruenberger, et al.
The Lancet. Oncology
|
July 5, 2005
Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial
Bernard Nordlinger, Philippe Rougier, Jean-Pierre Arnaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2020
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD
Hans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, et al.
Page
of 50
Search research articles
Search
Showing results (371-380 of 499) with videos related to
Sort By:
Page
of 50
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2021
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero, Axel Grothey, Eric Van Cutsem, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
March 13, 2021
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study
Wasat Mansoor, Hendrik-Tobias Arkenau, Maria Alsina, et al.
Future Oncology (London, England)
|
July 18, 2020
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements
Tanios S Bekaii-Saab, Juan W Valle, Eric Van Cutsem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2022
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Hedy L Kindler, Pascal Hammel, Michele Reni, et al.
The New England Journal of Medicine
|
June 4, 2019
Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer
Talia Golan, Pascal Hammel, Michele Reni, et al.
The Oncologist
|
March 31, 2010
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery
Sabine Tejpar, Monica Bertagnolli, Fred Bosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
90Y-edotreotide for metastatic carcinoid refractory to octreotide
David L Bushnell, Thomas M O'Dorisio, M Sue O'Dorisio, et al.
Annals of Surgery
|
February 9, 2012
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)
Halfdan Sorbye, Murielle Mauer, Thomas Gruenberger, et al.
The Lancet. Oncology
|
July 5, 2005
Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial
Bernard Nordlinger, Philippe Rougier, Jean-Pierre Arnaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2020
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD
Hans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, et al.
Page
of 50